• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Receive precise and cost-effective QT assessments with Early Precision QT (EPQT). Quality QT/QTc data is imperative in today’s competitive R&D market. Clario supported 70% of all new drug approvals from 2019-2020 offering a full range of support — from study design through submission — for formal Thorough QT studies and for assessing QT safety in clinical trials for which a traditional TQT study is not feasible.

Product detail

Confidently implement EPQT in your Phase 1 studies to enable earlier, more precise and cost-effective cardiac safety assessments and potentially qualify for a TQT waiver. The EPQT methodology was clinically proven in a comprehensive clinical trial, which concluded that ECGs collected and analyzed during routine early-phase studies could reliably provide cardiac safety information typically derived from dedicated TQT studies.

  • Understand QT and other ECG effects of a new drug and ensure compliance with ICH E14 Regulation
  • Obtain reliable, precise data earlier in development using clinically proven proprietary Early Precision QT methodology
  • Navigate unexpected issues throughout your trial by collaborating with our Phase 1 Center of Excellence
  • Partner with Clario Certified Sites who are well-trained and well-equipped to shorten study startup times and collect quality data
  • Ensure promising drugs and therapies aren’t eliminated due to inaccurate data

Clario has supported 3,600+ early phase cardiac studies.